Vertex Pharmaceuticals (VRTX) Share-based Compensation (2009 - 2026)

Vertex Pharmaceuticals' Share-based Compensation history runs 18 years deep, the most recent figure standing at $166.4 million for Q1 2026.

• In Q1 2026, Share-based Compensation changed 0.18% year-over-year to $166.4 million; the TTM figure through Mar 2026 stood at $370.2 million (up 9.66% YoY), while the FY2025 annual figure was $369.9 million, down 8.67% from the prior year.
• Share-based Compensation for Q1 2026 stood at $166.4 million, up from -$158.4 million in the prior quarter.
• The five-year high for Share-based Compensation was $233.5 million in Q1 2024, with the low at -$158.4 million in Q4 2025.
• The 5-year median for Share-based Compensation is $130.9 million (2023), against an average of $99.7 million.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation sank 172.14% in 2022, then surged 9833.33% in 2023.
• Vertex Pharmaceuticals' Share-based Compensation stood at $2.1 million in 2022, then soared by 9833.33% to $208.6 million in 2023, then tumbled by 160.26% to -$125.7 million in 2024, then declined by 26.01% to -$158.4 million in 2025, then surged by 205.05% to $166.4 million in 2026.
• Business Quant data shows VRTX's Share-based Compensation at $166.4 million in Q1 2026, -$158.4 million in Q4 2025, and $194.9 million in Q3 2025.